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In a randomized multicenter study, the efficacies of two dif-
ferent GnRH agonists were compared with that of hCG for
triggering final stages of oocyte maturation after ovarian hy-
perstimulation for in vitro fertilization. Ovarian stimulation
was conducted by recombinant FSH (Puregon), and the GnRH
antagonist ganirelix (Orgalutran) was coadministered for the
prevention of a premature LH rise. Luteal support was pro-
vided by daily progestin administration. Frequent blood sam-
pling was performed at midcycle in the first 47 eligible sub-
jects included in the current study, who were randomized for
a single dose of 0.2 mg triptorelin (n  17), 0.5 mg leuprorelin
(n  15), or 10,000 IU hCG (n  15). Serum concentrations of
LH, FSH, E2, and progesterone (P) were assessed at variable
intervals.
LH peaked at 4 h after both triptorelin and leuprorelin
administration, with median LH levels of 130 and 107 IU/liter
(P < 0.001), respectively. LH levels returned to baseline after
24 h. Subjects receiving hCG showed peak levels of 240 IU/liter
hCG 24 h after administration. A rise in FSH to 19 IU/liter (P <
0.001) was noted in both GnRH agonist groups 8 h after in-
jection. Within 24 h the areas under the curve for LH and FSH
were significantly higher (P < 0.001) in both GnRH agonist
groups compared with that for hCG. E2 and P levels were
similar for all groups up to the day of oocyte retrieval. Luteal
phase areas under the curve for P and E2 were significantly
elevated (P < 0.001) in the hCG group. The mean (SD) num-
bers of oocytes retrieved were 9.8 5.4, 8.7 4.5, and 8.3 3.3;
the percentages of metaphase II oocytes were 72%, 85%, and
86%; and fertilization rates were 61%, 62%, and 56% in the
triptorelin, leuprorelin, and hCG group, respectively (P  NS
for all three comparisons). These findings support the effec-
tive induction of final oocyte maturation in both GnRH ago-
nist groups.
In summary, after treatment with the GnRH antagonist
ganirelix for the prevention of premature LH surges, trigger-
ing of final stages of oocyte maturation can be induced effec-
tively by a single bolus injection of GnRH agonist, as demon-
strated by the induced endogenous LH and FSH surge and the
quality and fertilization rate of recovered oocytes. Moreover,
corpus luteum formation is induced by GnRH agonists with
luteal phase steroid levels closer to the physiological range
compared with hCG. This more physiological approach for
inducing oocyte maturation may represent a successful and
safer alternative for in vitro fertilization patients undergoing
ovarian hyperstimulation. (J Clin Endocrinol Metab 87:
709–715, 2002)
hCG REPRESENTS the standard of care for the substitu-tion of the endogenous LH surge to induce final stages
of oocyte maturation in ovarian hyperstimulation protocols
for in vitro fertilization (IVF). Unfortunately, hCG is also
believed to contribute to the occurrence of the ovarian hy-
perstimulation syndrome (OHSS), a potentially life-threat-
ening complication (1–3). Exogenous hCG is implicated in
the development of multiple corpora lutea and sustained
luteotropic effects due to its prolonged circulating half-life
compared with native LH (4–6). Moreover, the occurrence of
OHSS is associated with continued late luteal phase hCG
production in the case of pregnancy. An alternative to ex-
ogenous hCG could be the administration of a GnRH agonist
inducing an endogenous rise in both LH and FSH levels due
to the initial flare effect (5, 7). The capacity of GnRH agonists
to trigger ovulation after gonadotropin treatment of anovu-
latory women (8, 9) or to induce final stages of oocyte mat-
uration after ovarian hyperstimulation for IVF (5, 7, 10–12)
has been well established. The induction of an endogenous
LH (and FSH) surge is more physiological compared with the
administration of exogenous hCG and may reduce the risk
of OHSS due to the much shorter half-life of LH (10, 13, 14).
Moreover, under these conditions luteal phase steroid levels
seem closer to normo-ovulatory cycles (15), which may im-
prove endometrial receptivity (16, 17). Effects on oocyte qual-
ity and chances for subsequent fertilization remain uncertain
at this stage.
For obvious reasons, a GnRH agonist to induce oocyte
maturation can only be used when a GnRH agonist has not
been applied for pituitary down-regulation to prevent a pre-
mature LH rise during ovarian stimulation. As the GnRH
agonist long protocol has been the standard of care for over
Abbreviations: ANCOVA, Analysis of covariance; AUC, area under
the curve; ET, embryo transfer; ICSI, intracytoplasmatic sperm injection;
IVF, in vitro fertilization; OHSS, ovarian hyperstimulation syndrome; P,
progesterone.
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a decade, alternative approaches to induce oocyte matura-
tion has received little attention in recent years. The mid to
late follicular phase administration of a GnRH antagonist
may also be used to prevent a premature LH rise during
ovarian hyperstimulation. The recently introduced GnRH
antagonist ganirelix (Orgalutran, Antagon) competes with
native GnRH in binding to its receptor, resulting in the im-
mediate and dose-dependent suppression of endogenous
gonadotropin release (18, 19). In previous trials the daily
administration of 0.25 mg ganirelix has been shown to be safe
and effective (20), requiring, on the average, 5 d of treatment
and a reduced total dose of recombinant FSH compared with
a long GnRH agonist protocol (21–24). hCG has been used to
trigger final oocyte maturation in these first studies applying
GnRH antagonist. However, in contrast to GnRH agonist, the
suppressive effect of the GnRH antagonist can be reversed
immediately by administering native GnRH or GnRH ago-
nist, resulting in a surge of endogenous LH and FSH. This
new concept of triggering final oocyte maturation after
GnRH antagonist treatment was successfully tested in five
patients undergoing ovarian hyperstimulation for intrauter-
ine insemination using a single dose of 0.1 mg triptorelin (25).
No information on the maturity of oocytes could be obtained
in this first pilot study. In addition, a single dose of 0.2 mg
triptorelin was effective in triggering an endogenous LH
surge and final oocyte maturation in eight high responder
IVF patients cotreated with ganirelix (26). None of these
patients developed OHSS.
The current randomized study was designed to examine
whether, after daily late follicular phase treatment with 0.25
mg ganirelix, administration of a single dose of GnRH ag-
onist is at least as effective as hCG in inducing final oocyte
maturation in patients undergoing ovarian hyperstimulation
for IVF. Here we report on the endocrine profile and clinical
outcome of the first subset of patients in whom blood sam-
pling was performed at regular intervals after the adminis-
tration of triptorelin, leuprolide, or hCG.
Subjects and Methods
Subjects
The first 57 of 200 subjects participating in this comparative random-
ized trial signed informed consent, which included hospitalization to
monitor hormonal changes after GnRH agonist was given to trigger final
oocyte maturation. All subjects underwent ovarian hyperstimulation
with recombinant FSH for IVF plus intracytoplasmatic sperm injection
(ICSI) allowing for the assessment of oocyte maturation (metaphase II
stage). Subjects had a regular indication for ICSI, were between 18 and
39 yr of age, had a regular menstrual cycle (24–35 d) and body weight
was normal (body mass index, 18–29 kg/m2).
Study design
Six international centers participated in this study, and the protocol
was approved by the local ethics review committees. This study was an
open label, randomized, three-arm trial in subjects who started ovarian
hyperstimulation with recombinant FSH (Puregon, NV Organon, Oss,
The Netherlands) starting at cycle d 2 or 3 and continued treatment until
the day of inducing final oocyte maturation (Fig. 1). The FSH dose was
150 or 225 IU/d, sc, for the first 5 d of treatment. Thereafter, the daily
dose could be adjusted based on the follicular growth as observed by
ultrasound. To prevent premature LH surges, ganirelix (Orgalutran/
Antagon, NV Organon; 0.25 mg in 0.5 ml daily) was administered sc
starting on d 6 of FSH stimulation until and including the day of trig-
gering final oocyte maturation. On that day, randomization was per-
formed by means of an interactive telephone randomization system that
stratified for age, primary or secondary infertility, and number of fol-
licles at least 11 mm in diameter. Subjects were randomized in a ratio
of 1:1:1 to treatment with 0.2 mg triptorelin (Decapeptyl, Ferring Phar-
maceuticals Ltd., Copenhagen, Denmark), 0.5 mg leuprorelin (Lupron,
TAP Pharmaceuticals, Inc., Lake Forest, IL), or 10,000 IU hCG (Pregnyl,
NV Organon). Subjects were only randomized if at least three follicles
17 mm or larger were observed. High responders (defined as having25
follicles beyond 11 mm) were considered drop-outs from the study.
Approximately 30–36 h after triggering of final oocyte maturation, oo-
cyte retrieval was performed, followed by ICSI. No more than three
embryos were transferred at 2–5 d after oocyte retrieval. Exogenous
progesterone (P) was administered im for luteal support (Progestine, NV
Organon; 50 mg in 2 ml daily) from the day of embryo transfer (ET) for
at least 2 wk or until menses.
Assessments
Before the start of ovarian stimulation, pregnancy was excluded by
means of a hCG test, a blood sample was taken for hormone assessments,
and ultrasound was performed. The subject returned to the clinic at least
once every 2 d for ultrasound investigation and blood sampling from d
6 of stimulation until the day of triggering of final oocyte maturation.
Blood sampling was performed before ganirelix and FSH administra-
tion. On the day of triggering final oocyte maturation, blood samples
were taken just before GnRH agonist or hCG administration; at 2, 4, 8,
12, and 24 h after GnRH agonist injection; and at 12 and 24 h after hCG
injection. Additional blood samples of all subjects were taken on the day
of oocyte pick-up, on the day of ET, and 1 and 2 wk after ET. hCG
concentrations were not assessed at 4 and 8 h because previous phar-
macokinetic studies (27) demonstrated a cmax at 20 h.
Serum FSH, LH, E2, hCG, and P levels were assessed by a central
laboratory using fluoroimmunoassays (Delfia, Wallac, Inc. OY, Turku,
Finland). Detection limits of these assays were less than 1 IU/liter for
FSH, less than 0.6 IU/liter for LH, less than 14 pg/ml for E2, less than
2.0 IU/liter for hCG, and less than 0.3 ng/ml for P. Intra- and interassay
coefficients of variation were 1.6% and 4.1% for FSH, 11.0% and 13.0%
for LH, 7.8% and 10.3% for E2, 6.9% and 9.3% for hCG, and 5.0% and
6.9% for P, respectively.
Embryo quality was assessed as grade 1 (excellent embryos with
absent fragmentation), grade 2 (1–20% fragmentation), grade 3 (21–50%
fragmentation), or grade 4.
Statistical methods
The primary objective of this study was to compare endocrine char-
acteristics of both GnRH agonist groups vs. hCG to induce final oocyte
FIG. 1. Schematic representation of different treatment
regimens for ovarian hyperstimulation for IVF using re-
combinant FSH and ganirelix to prevent a premature rise
in LH, followed by the triggering of final oocyte maturation
by a single dose of two GnRH agonists (triptorelin or leu-
prorelin) or hCG.
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maturation. Relevant data of leuprorelin, triptorelin, and hCG have been
statistically compared using analysis of covariance (ANCOVA) with
center and treatment as factors and endocrine or ultrasound features as
covariate. In case the overall treatment factor was statistically significant
(i.e. the three treatment groups differ statistically significant), pairwise
comparisons were made between hCG and leuprorelin or triptorelin,
respectively. These pairwise comparisons were performed using the
same analysis of covariance.
Individual areas under the curve (AUC) were calculated using the
linear trapezoidal rule. For LH and FSH the concentrations obtained on
the day of triggering final oocyte maturation up to 24 h after GnRH
agonist or hCG injection were included in the AUC. For E2 and P the
applied timeframe was from the day of triggering of final oocyte mat-
uration until 2 wk after ET. To correct for possible differences in the
timeframes, each AUC value was divided by the actual timeframe,
resulting in individual estimates of the mean hormone concentration
over time. Descriptive statistics were calculated for these derived con-
centrations per treatment (Table 1), and a one-way ANCOVA was per-
formed to compare the treatment effects of both leuprorelin and trip-
torelin vs. hCG. In case the ANCOVA showed statistically significant
differences among the three treatment groups, two-sample t tests were
performed to compare both leuprorelin and triptorelin vs. hCG,
respectively.
Preliminary clinical outcome parameters are described for all ran-
domized patients (using descriptive statistics unadjusted for center)
showing no major differences (Table 2). Definitive statistical evaluation
will be performed separately on the extended series of women (as
described above under Subjects).
P  0.05 was considered to represent a statistically significant
difference.
Results
Disposition and cancellations
A total of 57 subjects started treatment with FSH, of whom
47 were randomized. Eight subjects (14%) were not random-
ized due to insufficient ovarian response to stimulation. Two
subjects were not randomized due to high response. One
subject in the hCG group did not undergo ET due to a
fertilization failure.
Characteristics of randomized subjects
The overall mean age was 30.4 4.2 yr, height was 1.67
0.07 m, weight was 64.6  7.7 kg, and body mass index was
23.3  2.5 kg/m2. The vast majority of subjects (98%) par-
ticipating in this study were Caucasian. The three treatment
groups were similar with respect to age, height, weight, and
body mass index (data not shown).
The total amount of exogenous FSH required (mean sd,
1579  395, 1665  455, and 1605  544 IU for triptorelin,
leuprorelin, and hCG, respectively), the duration of FSH
stimulation (8.6 1.1, 9.2 1.6, 9.3 2.0 d), and the duration
of ganirelix treatment (4.6  1.1, 5.1  1.7, and 5.3  2.0 d)
were similar (P  NS for all these prerandomization param-
eters) in the three treatment groups. The overall median
duration of stimulation was 9 d (range, 6–14 d), and the
median total amount of exogenous FSH administered was
1500 IU (range, 900-2625 IU). The median duration of gani-
relix treatment was 5 d (range, 2–10 d). The mean numbers
of follicles 11 mm or larger per treatment group assessed on
d 1, 6, and 8 of stimulation and on the day of randomization
for induction of final oocyte maturation are presented in Fig.
2. On the day of the last ultrasound investigation before
triggering of final oocyte maturation the mean numbers of
follicles 17 mm or larger were 4.8  2.2, 4.6  1.8, and 4.3 
1.4 (PNS) for the triptorelin, leuprolide, and hCG groups,
respectively.
FIG. 2. Number of follicles 11 mm or larger (mean  SD) assessed on
stimulation d 1, 6, and 8 and on the day of triggering of final oocyte
maturation (by triptorelin, leuprorelin, or hCG) during ovarian hy-
perstimulation for IVF with exogenous FSH.
TABLE 1. Area under the curve divided by the actual time period
for serum hormone concentrations (mean  SD) during triggering
of final oocyte maturation with the GnRH agonists (triptorelin and
leuprorelin) or hCG following ovarian hyperstimulation for IVF
(0–24h for LH and FSH) and during the subsequent luteal phase
(0–2 wk for E2 and P)
Triptorelin
(n  15)
Leuprorelin
(n  15)
hCG
(n  15)
LH(0–24h) (IU/L)
a 59  14b 53  14b 2.7  2.2
FSH(0–24h) (IU/L)
a 14.5  3.8b 14.3  3.7b 5.0  1.2
E2(0–2 wk) (pg/ml)
a 252  154b 196  111c 515  286
P(0–2 wk) (ng/ml)
a 12.5  7.7b 15.2  7.1b 37.8  17.1
a PANCOVA  0.001 comparing all three groups.
b P  0.0001 vs. hCG group (paired t test).
c P  0.0006 vs. hCG group (paired t test).
TABLE 2. Clinical outcome (mean  SD) of a randomized
comparison between two GnRH agonists (triptorelin and
leuprorelin) vs. hCG in inducing final oocyte maturation after
ovarian hyperstimulation with FSH and cotreatment with
ganirelix in 47 IVF patients
Triptorelin
(n  17)
Leuprorelin
(n  15)
hCGa
(n  15)
Number of
oocytes/subject
9.8  5.4 8.7  4.5 8.3  3.3
Proportion of metaphase
II oocytes
72  18% 85  17% 86  17%
Fertilization rate 61  30% 62  23% 56  18%
Number of embryos
obtained/subject
Good quality (grade 1) 0.5  0.9 1.6  1.8 0.8  0.9
Good quality (grade 2) 1.9  1.8 2.7  2.5 1.7  1.9
Grades 1 and 2 pooled 2.7  1.9 3.2  2.6 3.3  2.0
Implantation rate 15  34% 18  37% 7  14%
Ongoing pregnancy
rateb
18% 20% 13%
a P  NS for all features comparing the triptorelin or the leupro-
relin group vs. women receiving hCG.
b Defined as a pregnancy per IVF cycle, confirmed by detection of
positive heart beat on ultrasound between 12 and 16 wk of gestation.
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Serum hormone levels
Serum concentrations of LH, FSH, E2, and P measured at
regular intervals after triggering final oocyte maturation up
to 2 wk after ET are presented in Fig. 3. An endogenous LH
rise was observed in all subjects who received either trip-
torelin or leuprorelin. In both treatment groups serum LH
levels rapidly increased and reached peak levels 4 h after
GnRH agonist administration. Mean (sd) LH levels in-
creased from 0.9 0.4 IU/liter before triggering oocyte mat-
uration to peak levels of 130  60 IU/liter after triptorelin
administration (P  0.001) and from 0.9  0.8 to 107  55
IU/liter after leuprorelin administration (P  0.001). On the
day of oocyte pick-up LH levels returned to baseline (4.8 
2.5 in the triptorelin group and 2.6  0.4 IU/liter in the
leuprorelin group). In subjects randomized to hCG treat-
ment, serum hCG levels increased gradually and reached a
peak of 240  101 IU/liter at 24 h after administration.
Thereafter, serum hCG levels declined to 5.0  1.6 IU/liter
1 wk after ET. After hCG administration, serum LH remained
low or undetectable during the entire luteal phase. In con-
trast to hCG-treated subjects, FSH levels increased after
GnRH agonist administration. FSH levels increased from
5.8 1.6 IU/liter before induction of final oocyte maturation
to 19.2  5.2 IU/liter at 8 h after GnRH agonist administra-
tion in the triptorelin group. In the leuprorelin group these
levels increased from 5.2  1.6 to 19.7  5.1 IU/liter (P 
0.001 for both groups), whereas in the hCG group serum FSH
levels declined after hCG administration from 5.8  1.6 to
3.4  0.8 IU/liter (P  0.001) on the day of oocyte pick-up,
reflecting the clearance of exogenous FSH. The individual
AUCs for LH and FSH within the first 24 h are depicted in
Table 1, confirming the major difference comparing both
GnRH agonist groups vs. hCG.
Serum E2 and P levels were comparable from the time of
triggering ovulation until oocyte pick-up (see Fig. 3). There-
after, serum E2 and P levels remained higher in hCG-treated
subjects compared with both GnRH agonist groups. Respec-
tive mean (sem) E2 levels were 279  48, 204  30, and
609  115 pg/ml on the day of ET (PANCOVA  0.0002;
Ptriptorelin vs. hCG 0.0006; Pleuprorelin vs. hCG 0.0001), and
46 4, 45 9, and 490 145 pg/ml 1 wk thereafter (PANCOVA
 0.0001; Ptriptorelin vs. hCG  0.0001; Pleuprorelin vs. hCG 
0.0001) in triptorelin-, leuprorelin-, and hCG-treated subjects,
respectively. Mean P levels were 7.2  1.7, 8.0  1.5, and
58.6  9.6 ng/ml on the day of transfer (PANCOVA  0.0001;
Ptriptorelin vs. hCG  0.0001; Pleuprorelin vs. hCG  0.0001) and
18.0  3.6, 23.2  3.7, and 45.9  11.2 ng/ml 1 wk later
(PANCOVA 0.0006; Ptriptorelin vs. hCG 0.0002; Pleuprorelin vs.
hCG  0.0054). At the end of the luteal phase, levels of both
hormones were comparable in the three treatment groups.
The luteal phase AUCs (Table 1) confirmed elevated E2 and
P levels in the hCG group.
Clinical outcome
The clinical outcome (number of oocytes retrieved, per-
centage of metaphase II oocytes, fertilization rates, embryo
quality, and implantation rates) is presented in Table 2. The
numbers of miscarriages within the first 12 wk after transfer
were 3, 2, and 3 in the triptorelin-, leuprorelin-, and hCG-
treated subjects, respectively.
FIG. 3. Serum concentrations of LH (hCG), FSH, E2, and P (mean  SEM) during triggering of final stages of oocyte maturation (0, 4, 8, 12,
and 24 h) with two GnRH agonist (triptorelin and leuprorelin) or hCG after ovarian hyperstimulation for IVF and during the subsequent luteal
phase [day of oocyte pick-up (OPU), embryo transfer (ET), and 1 and 2 wk after ET].
712 J Clin Endocrinol Metab, February 2002, 87(2):709–715 Fauser et al. • Ganirelix in Ovarian Hyperstimulation for IVF
 at Medical Library Erasmus MC on November 20, 2006 jcem.endojournals.orgDownloaded from 
Discussion
In the normal menstrual cycle the midcycle LH and FSH
surge (lasting for 48 h) is a complex and carefully orches-
trated event elicited in the late follicular phase by persistently
elevated estrogen concentrations in combination with a
small, but distinct, rise in P (28). Exposure to a transient
massive stimulation by LH elicits the resumption of meiotic
maturation of the oocyte, rupture of the dominant follicle
resulting in the release of the oocyte, and luteinization of
thecal and granulosa cells resulting in the formation of the
corpus luteum. The timing of the endogenous LH surge is
frequently disrupted if exogenous FSH is administered either
for ovarian hyperstimulation for IVF or for the treatment of
anovulation. Therefore, exogenous hCG (which activates the
LH receptor due to structural and biological similarities to
LH and which is easy to extract from urine of pregnant
women) has been used for decades to replace endogenous
LH during FSH stimulation protocols. hCG has been shown
to effectively induce ovulation, final oocyte maturation, and
corpus luteum formation. However, hCG has an extended
MCR (4, 27), and therefore hCG can still be detected in the
serum 10 d after the preovulatory bolus injection. Conse-
quently, continued support of the corpus luteum by hCG
elicits supraphysiological luteal phase steroid concentra-
tions. Moreover, hCG in the late follicular phase may stim-
ulate the growth of medium-sized follicles (3, 29, 30), which
may subsequently ovulate. A midcycle bolus dose of hCG
induces elevated follicular fluid P levels, suggesting changes
in the microenvironment of the oocyte just before ovulation
compared with the endogenous LH surge (31).
Next to a hyperresponse of the ovary to stimulation (i.e.
large late follicular phase number of follicles and very high
E2 levels), both exogenous and endogenous hCG have clearly
been associated with OHSS (32–34). The induction and stim-
ulation of multiple corpora lutea may represent a key phe-
nomenon in this regard. Although luteal phase support by
repeated hCG injections has been clearly shown to be ben-
eficial in IVF (35), randomized comparative trials have also
convincingly demonstrated a higher incidence of OHSS in
these patients (36, 37). Therefore, luteal function in IVF cycles
is currently supplemented by exogenous P. Moreover, it has
been shown that the late and most severe form of OHSS
occurs especially in multiple pregnancies (coinciding with
elevated hCG production) (32, 34). Indeed, withholding hCG
along with discontinuation of ovarian stimulation effectively
prevents ovulation, pregnancy, and the development of
OHSS in women presenting with an excessive ovarian re-
sponse. Other approaches for the prevention of OHSS in-
clude withholding gonadotropins for some days during the
late follicular phase (also referred to as coasting), reducing
the hCG bolus dose, replacing hCG with GnRH agonist as
addressed in the current study, the administration of glu-
cocorticoids or albumen, the avoidance of luteal support by
hCG, and cryopreservation of embryos and transfer in sub-
sequent cycles.
It has been clearly shown in several animal models that the
midcycle gonadotropin surge is accompanied by a major rise
in endogenous GnRH in the portal circulation (38). Indeed,
several initial studies in IVF showed that a midcycle endog-
enous LH rise could be induced by the late follicular phase
administration of exogenous GnRH or GnRH agonist. In-
duction of final oocyte maturation with GnRH agonists in
patients undergoing ovarian hyperstimulation is believed to
be more physiological and of special benefit to high respond-
ers with an increased risk of developing OHSS. In the current
study very high hCG levels (median, 200 IU/liter) lasted
for 24 h (from 12–36 h after triggering of oocyte maturation),
and clearance of the 10,000 IU hCG required around 10 d.
Although effective, the approach to induce oocyte matu-
ration by midcycle GnRH agonist administration lost interest
during the nineties, as ovarian hyperstimulation protocols
also included GnRH agonist coadministration to suppress a
premature rise in LH during the follicular phase. This ren-
ders the pituitary in a state of desensitization, precluding
stimulation of the endogenous LH surge. Several recent stud-
ies have shown that short-term GnRH antagonist adminis-
tration during the late follicular phase is also effective in
preventing a premature LH rise. This blockage of GnRH
receptors on the gonadotropic cells by the antagonist can be
reversed by GnRH stimulation, allowing reevaluation of
stimulating a midcycle rise in endogenous LH. The primary
purpose of the current study was to investigate the dynamics
of the midcycle gonadotropin surge under these circum-
stances. The current study also demonstrates for the first time
that final maturation of oocytes can be triggered with GnRH
agonists rather than hCG after ovarian hyperstimulation us-
ing ganirelix to prevent a premature LH rise. An adequate
pituitary response in terms of a rise in endogenous LH and
FSH was observed after the administration of either 0.2 mg
triptorelin or 0.5 mg leuprorelin, and luteal phase steroid
levels were closer to the physiological range.
Endogenous LH and FSH surges in the current study were
comparable to those described after triggering of oocyte mat-
uration using GnRH agonists in nonsuppressed subjects un-
dergoing ovarian stimulation for IVF (5, 7). Thus, in the
current study the doses of GnRH agonist administered 12 h
after the last antagonist injection were sufficient to displace
ganirelix from the GnRH receptors. The maximum LH and
FSH levels were comparable to circulating midcycle LH and
FSH levels in natural cycles (28). In a recent preliminary
study (also applying 0.2 mg triptorelin for triggering of oo-
cyte maturation in eight high responder patients treated with
exogenous FSH and 0.25 mg ganirelix) higher maximum LH
concentrations compared with the current study were re-
ported (26). This may indicate that the magnitude of the LH
surge is in part determined by the endocrine status of the
patient, as high response patients were excluded from the
current study. In the current study the duration of the LH
surge appeared to be shorter compared with that in the
natural cycle (24 vs. 36–48 h, respectively). This phenomenon
might be explained by the immediate pituitary desensitiza-
tion after the initial flare effect, as two doses of buserelin 12 h
apart resulted in similar LH profiles (7). Despite the shorter
duration compared with physiological conditions, the in-
duced LH surge effectively stimulated final oocyte matura-
tion, as reflected by the high percentage of metaphase II
oocytes (72–85%) as well as good fertilization and embryo
implantation rates.
An alternative means of mimicking the midcycle gonad-
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otropin surge is the administration of a high dose of recom-
binant LH (39). However, the relatively short half-life of this
compound (40) suggests that very high or multiple doses
should be given. A recently published large randomized
comparative trial showed the complete absence of OHSS in
women receiving a single dose of recombinant LH in doses
up to 30,000 IU (41). Extensive studies in the monkey using
different doses of LH or hCG suggest that the duration of the
midcycle LH surge is critical for inducing a normally func-
tioning corpus luteum (42, 43). A relatively short LH surge
resulted in normal oocyte maturation and ovulation,
whereas luteal phase length was reduced, implying that lu-
teal support is required under these conditions. In the current
study serum E2 and P levels were comparable for all treat-
ment groups up to the day of oocyte retrieval. However,
thereafter both E2 and P levels were higher in hCG-treated
subjects. This difference can be explained by the prolonged
half-life of hCG compared with LH, which is responsible for
continued support of the corpus luteum. These luteal phase
steroid levels far above the physiological range may suppress
the release of endogenous gonadotropins required for corpus
luteum support (44) and may exhibit a negative impact on
endometrial receptivity (16, 17). In the current study luteal
phase supplementation was applied by daily progestin ad-
ministration. Therefore, the dynamics of midcycle LH re-
quirements for subsequent normal luteal function in the hu-
man require further investigation.
The physiological role of the midcycle FSH surge that
occurs in the natural cycle has not been elucidated to date,
but recent studies suggest that FSH may play a role in the
process of nuclear maturation by actively promoting re-
sumption of meiosis (45, 46). Moreover, studies in the rat
have demonstrated that a high dose of FSH alone is capable
of inducing ovulation (47). On the other hand, a midcycle
FSH surge is not mandatory, as normal oocyte maturation
and ovulation occur after the administration of hCG. The
potential favorable impact of a GnRH agonist-induced FSH
surge is unknown at present.
In summary, the application of a single dose of GnRH
agonist was shown to be effective in inducing a gonadotropin
surge and triggering final oocyte maturation in normal re-
sponder patients after ovarian hyperstimulation for IVF co-
treated with GnRH antagonist. Effects on the dynamics of the
pituitary-ovarian axis during the luteal phase along with its
capacity to prevent OHSS require further evaluation. This
more physiological approach to inducing oocyte maturation
may provide a successful and safer alternative for patients
undergoing IVF.
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